IMOJEV
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Japanese Encephalitis
Conditions
Japanese Encephalitis
Trial Timeline
Jul 11, 2013 → Mar 11, 2014
NCT ID
NCT01900444About IMOJEV
IMOJEV is a phase 3 stage product being developed by Sanofi for Japanese Encephalitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01900444. Target conditions include Japanese Encephalitis.
What happened to similar drugs?
3 of 20 similar drugs in Japanese Encephalitis were approved
Approved (3) Terminated (0) Active (17)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01900444 | Phase 3 | Completed |
Competing Products
20 competing products in Japanese Encephalitis